Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes

AIM: Our aim was to investigate the effects of add-on canagliflozin with glimepiride dose adjustment or glimepiride dose adjustment on pancreatic beta cell function in patients with type 2 diabetes mellitus and inadequate glycemic control despite stable triple therapy (metformin, teneligliptin, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahara, Mitsuyoshi, Shiraiwa, Toshihiko, Matsuoka, Taka-aki, Yamamoto, Kaoru, Maeno, Yoshifumi, Shiraiwa, Yuka, Yoshida, Yoko, Katakami, Naoto, Iijima, Hiroaki, Katsumata, Hideyuki, Arakawa, Kenji, Hashimoto, Toshio, Shimomura, Iichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683829/
https://www.ncbi.nlm.nih.gov/pubmed/33244248
http://dx.doi.org/10.2147/DMSO.S273396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683829/
https://www.ncbi.nlm.nih.gov/pubmed/33244248
http://dx.doi.org/10.2147/DMSO.S273396

Ejemplares similares